Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials

File(s)

Genetic risk paper, Lancet Mega et al.docx (288.24 KB)

Accepted version

Show more

Author(s)

Mega, JL

Stitziel, NO

Smith, JG

Chasman, DI

Caulfield, MJ

more

Type

Journal Article

Date Issued

2015-06-06

Date Acceptance

2015-02-11

Citation

LANCET, 2015, 385 (9984), pp.2264-2271

URI

http://hdl.handle.net/10044/1/52525

DOI

https://www.dx.doi.org/10.1016/S0140-6736(14)61730-X

ISSN

0140-6736

Publisher

ELSEVIER SCIENCE INC

Start Page

2264

End Page

2271

Journal / Book Title

LANCET

Volume

385

Issue

9984

Copyright Statement

© 2015, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

Sponsor

National Institute for Health Research

Imperial College Healthcare NHS Trust- BRC Funding

National Institute for Health Research

National Institute for Health Research

Identifier

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000355943500028&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Grant Number

NF-SI-0510-10055

RDC02 79560

n/a

NF-SI-0513-10059

Subjects

Science & Technology

Life Sciences & Biomedicine

Medicine, General & Internal

General & Internal Medicine

RECURRENT MYOCARDIAL-INFARCTION

CARDIOVASCULAR-DISEASE

ARTERY-DISEASE

SUSCEPTIBILITY LOCI

RANDOMIZED-TRIALS

LDL CHOLESTEROL

CHROMOSOME 9P21

GRACE GENETICS

CARDIAC DEATH

POLYMORPHISMS

Publication Status

Published